ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

zefamenib

Also written as “BN104 monotherapy”, “BN104 monotherapy - rp2d” and “BN104”.

Its studies are mostly in Precursor Cell Lymphoblastic Leukemia-Lymphoma, led by 2 companies.

Drug pageZefamenib: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Dec 2, 20242 company-led studies, 1 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioNova Pharmaceuticals (Shanghai)its history only10 open or runningphase 1since Dec 2, 2024Dec 2, 2024none ahead
Institut de Recherches Internationales Servier (I.R.I.S.)11 open or runningphase 2since Sep 6, 2023Sep 6, 2023Dec 2026phase 2 · NCT06052813

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Institut de Recherches Internationales Servier (I.R.I.S.) only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Sep 6, 2023First study: phase 2 study in Precursor Cell Lymphoblastic Leukemia-LymphomaFirst studyNCT06052813 · 66 enrolled · China
  2. Jul 10, 2025Named zefamenibINNProposed as its International Nonproprietary Name in WHO's List 133 · before, BN104

Ahead

  1. Dec 2026Primary completion: phase 2 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNCT06052813

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Institut de Recherches Internationales Servier (I.R.I.S.) leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06052813Precursor Cell Lymphoblastic Leukemia-Lymphoma · China2Active, not recruitingDec 202666

How it is read

Names in the registry

  • “BN104 monotherapy”, 2 entries
  • “BN104 monotherapy - rp2d”, 1 entry
  • “BN104”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.